

Propofol Modulation of $\alpha 1$ Glycine Receptors Does Not Require a Structural Transition at Adjacent Subunits That Is Crucial to Agonist-Induced Activation


Timothy Lynagh,* Alexander Kunz, and Bodo Laube

Neurophysiology and Neurosensory Systems, Technische Universität Darmstadt, Schnittspahnstrasse 3, 64287 Darmstadt, Germany

S Supporting Information

ABSTRACT: Pentameric glycine receptors (GlyRs) couple agonist binding to activation of an intrinsic ion channel. Substitution of the R271 residue impairs agonist-induced activation and is associated with the human disease hyperekplexia. On the basis of a homology model of the $\alpha 1$ GlyR, we substituted residues in the vicinity of R271 with cysteines, generating R271C, Q226C, and D284C single-mutant GlyRs and R271C/Q226C and R271C/D284C double-mutant GlyRs. We then examined the impact of interactions between these positions on receptor activation by glycine and modulation by the anesthetic propofol, as measured by electrophysiological experiments. Upon expression in *Xenopus laevis* oocytes, D284C-containing receptors were nonfunctional, despite biochemical evidence of successful cell surface expression. At R271C/Q226C GlyRs, glycine-activated whole-cell currents were increased 3-fold in the presence of the thiol reductant dithiothreitol, whereas the ability of propofol to enhance glycine-activated currents was not affected by dithiothreitol. Biochemical experiments showed that mutant R271C/Q226C subunits form covalently linked pentamers, showing that intersubunit disulfide cross-links are formed. These data indicate that intersubunit disulfide links in the transmembrane domain prevent a structural transition that is crucial to agonist-induced activation of GlyRs but not to modulation by the anesthetic propofol and implicate D284 in the functional integrity of GlyRs.

KEYWORDS: Ligand-gated ion channel, transmembrane domain, activation mechanism, propofol, cross-linking, Cys-loop receptor



Ligand-gated ion channels (LGICs) are membrane-bound proteins that couple neurotransmitter binding in a large extracellular domain (ECD) with the opening of an intrinsic ion channel in a transmembrane domain (TMD). Thus, they rapidly convert extracellular chemical signals into electrical signals at the cell membrane, determining excitation or inhibition of further signal transmission.¹ On the basis of distinct structural features, LGICs can be divided into families of trimeric ATP-activated channels, tetrameric glutamate-activated channels, and the large family of pentameric LGICs (“pLGICs” or “Cys-loop receptors”). The latter includes inhibitory glycine receptors (GlyRs), glycine-activated chloride channels that are widely distributed in the spinal cord and some higher centers, where they contribute to motor control and various other functions.² Human GlyRs consist of five homologous subunits, either five $\alpha 1$, $\alpha 2$, and $\alpha 3$ subunits or a mix of α and β subunits, arranged in 5-fold symmetry around a central pore.² Single GlyR subunits consist of a large N-terminal ECD and a C-terminal TMD comprised of four membrane-spanning helices (M1–M4). The ligand binding domain (LBD) is formed at the interface of adjacent ECDs, and the channel is formed by the central apposition of five M2 helices. This arrangement is well-conserved throughout the family, which also includes the excitatory nicotinic acetylcholine receptors (nAChRs) and 5-HT type 3 receptors (5-HT₃Rs)

and the inhibitory γ -aminobutyric acid type A receptors (GABA_ARs).

Numerous mutagenesis studies have identified amino acid residues that determine ligand recognition in the LBD and ion conductance in the TMD of GlyRs; however, the coordinated movement of individual residues required by ligand activation of, for example, nAChRs³ is relatively unresolved in GlyRs. This rearrangement of individual residues is of great physiological importance, as exemplified by the arginine residue at position 271 (R271) at the extracellular end of M2 in the $\alpha 1$ GlyR. In recombinantly expressed receptors, substitution of this residue weakens both the preference of the channel for states of high conductance^{4,5} and the transition from closed to open states subsequent to glycine binding.^{5,6} Also in recombinant receptors, the fluorescent signal of a thiol-reactive fluorophore bound to an introduced cysteine at this position is shifted to lower wavelengths, suggesting that during activation by glycine, the residue at position 271 enters a more hydrophobic environment.⁷ *In vivo*, the decreased level of activation of R271-mutated $\alpha 1$ GlyRs results in neuronal hyperexcitability

Received: July 10, 2013

Accepted: August 30, 2013

Published: August 30, 2013

and the condition known as hyperekplexia or startle disease.⁸ The arrangement of this residue within the receptor is also of pharmacological significance, as side chain properties of R271 and other vicinal residues may contribute to GlyR sensitivity to widely used drugs such as ethanol and the anesthetic propofol, which both enhance responses to glycine.^{9,10} Notably, enhancement by propofol remains intact in R271 mutant $\alpha 1$ GlyRs^{11,12} and is capable of restoring normal function on R271 mutant receptors, both in recombinant settings and in hyperekplexic mice.¹¹

We sought to establish the structural arrangement of R271 and its rearrangement in both activation by agonists and enhancement of activation by propofol, as a basis for understanding the importance of this position in receptor function. We employed a site-directed cross-linking technique,¹³ whereby open-channel or closed-channel conformations can be mimicked by introducing a pair of vicinal cysteine residues and promoting disulfide links.¹⁴ We present electrophysiological and biochemical evidence of a disulfide link between introduced cysteines at the M2-R271 and M1-Q226 positions of adjacent subunits, implying that these positions are in the proximity of each other in functional $\alpha 1$ GlyRs. We find that the linking of two subunits via these positions decreases the efficiency of channel activation by full and partial agonists but has no effect on the enhancement by propofol.

RESULTS AND DISCUSSION

Positions R271 in M2 and Q226 in M1 of the $\alpha 1$ GlyR Are in the Proximity of Each Other. The introduction of a cysteine pair into $\alpha 1$ GlyR subunits introduces 10 cysteine residues into the mature pentameric protein. Therefore, reaching a conclusion about which two cysteines are linked requires exhaustive experiments and/or high-resolution structural data. Although the atomic structure of GlyRs is unknown, ~ 3 Å resolution data of prokaryotic and invertebrate pLGICs have recently been published,^{15–17} providing a structural template for assessing GlyR cross-linking results. In estimating the arrangement of R271 in the $\alpha 1$ GlyR, we used a previously published model of the $\alpha 1$ GlyR¹⁸ based on the crystal structure of the glutamate- and ivermectin-bound *Caenorhabditis elegans* α glutamate-gated chloride channel (GluCl).¹⁶ In the model, the R271 side chain is directed away from the central pore of the pentamer, toward the intersubunit cavity, such that its guanidino carbon is 4.1 Å from the carboxyl carbon of D284 in M3 of the same subunit and 3.6 Å from the amide carbon of Q226 in M1 of the adjacent subunit (Figure 1a). To test the possibility that in the $\alpha 1$ GlyR, R271 is in the proximity of D284 or Q226, we substituted these residues for cysteine, alone and in pairs, generating wild-type (WT), R271C, Q226C, D284C, R271C/Q226C, and R271C/D284C $\alpha 1$ GlyR constructs. Each construct also incorporated the C290S mutation, which was functionally silent (Figure 1 of the Supporting Information) and eliminated possible interactions between introduced cysteines and this endogenous M3 cysteine. We expressed each construct in *Xenopus laevis* oocytes and measured current responses to saturating concentrations of glycine alone or in the presence of either dithiothreitol (DTT) or HgCl₂, which keep cysteine residues reduced or bridge unlinked cysteine residues within sufficient proximity, respectively.^{19,20}

Oocytes treated with D284C or R271C/D284C $\alpha 1$ GlyR cRNA showed no response to glycine, alone or in the presence of DTT, HgCl₂, or propofol ($n = 7–10$ over three batches of




Figure 1. (a) Position of R271 and proximal residues in the $\alpha 1$ GlyR homology model. The pentameric structure is shown (top left), and the interface of two adjacent subunits (boxed area) is shown in greater detail, with one subunit colored gray and one black. Arrows indicate the 4.1 and 3.6 Å separation of M2-R271 ζ C from M3-D284 γ C and M1-Q226 δ C, respectively. The distance from the M2-R271 ζ C atom to that from adjacent subunits is 20.5 Å (not shown). The model, which was described previously,¹⁸ used as a template the glutamate- and ivermectin-activated *C. elegans* α GluCl crystal structure¹⁶ (Protein Data Bank entry 3R1F). (b) Cell surface expression of mutant $\alpha 1$ GlyR subunits. Oocytes were treated with mutant D284C or R271C/Q226C $\alpha 1$ GlyR cRNAs and either rinsed with the membrane-impermeable fluorophore Cy5, purified, separated by SDS-PAGE, and imaged (left) or separated by SDS-PAGE, subjected to $\alpha 1$ GlyR-specific Western blotting, and imaged. Both experiments identified single $\alpha 1$ GlyR subunits (~ 48 kDa protein bands) that were insensitive to Endo H cleavage, indicating cell surface expression. Electrophysiological experiments showed that D284C $\alpha 1$ GlyRs were not responsive to glycine, whereas R271C/Q226C $\alpha 1$ GlyRs were.

oocytes). (This was also the case when the C290S mutation was absent; see the legend of Figure 1 of the Supporting Information.) This indicates that the D284C mutation either prevents responses to glycine in expressed receptors or prevents the expression or assembly of receptors. To establish which possibility is correct, we incubated D284C $\alpha 1$ GlyR-expressing oocytes with the membrane-impermeable fluorophore Cy5 NHS ester and subsequently purified and imaged GlyRs under denaturing conditions. This revealed ~ 48 kDa bands of protein that were insensitive to Endo H cleavage (Figure 1b, left panel), indicative of cell surface-expressed $\alpha 1$ GlyR subunits.²¹ As Cy5 labels yielded a weak fluorescent signal, we performed a similar experiment but probed for $\alpha 1$ GlyR expression with an anti- $\alpha 1$ GlyR primary antibody and a horseradish peroxidase-conjugated secondary antibody. This too showed Endo H-insensitive expression of D284C $\alpha 1$ GlyRs

(Figure 1b, right panel). The extent of expression seemed similar to the extent for R271C/Q226C $\alpha 1$ GlyRs (Figure 1b), which were used as a functional (as shown in electrophysiological experiments, below) control. Thus, the lack of agonist responses at mutant D284C $\alpha 1$ GlyRs is due to the inability to function after successful cell surface expression. We note that substitutions of the equivalent aspartate residue in $\alpha 1$ or $\beta 2$ subunits of GABA_ARs also result in little or no response to the agonist.²²

The peak magnitude of responses of R271C/Q226C receptors to glycine was significantly increased in the presence of 2 mM DTT and unaffected by 10 μ M HgCl₂, whereas WT and single-mutant receptors were not significantly affected by either treatment (Figure 2a,b). This indicates that in R271C/Q226C receptors, the introduced cysteines form a disulfide bond; the presence of DTT breaks this bond, resulting in a greater whole-cell current response to glycine. Thus, C α atoms of positions 271 and 226 are likely separated by approximately 6 Å in at least one functional state of the receptor.^{23,24} Although not significant, there was a trend toward stronger responses at R271C receptors in the presence of HgCl₂ (Figure 2b), raising the possibility that nonsymmetrical movement of adjacent M2 helices brings two position 271 C α atoms within 8 Å of each other.^{19,25} We also treated oocytes with a 1:1 mix of single-mutant R271C and Q226C cRNAs. Assuming that R271C subunits and Q226C subunits are expressed with similar efficiency, this produces a mix of R271C homomers, R271C–Q226C heteromers of varying stoichiometry, and Q226C homomers. None of these receptors contain two introduced cysteines in a single subunit, and they thus provide a means of testing whether the observed disulfide link occurs within single subunits or across adjacent subunits.²⁶ At these oocytes, responses to glycine were significantly enhanced in the presence of DTT, to an extent similar to that of oocytes expressing homomeric R271C/Q226C receptors (Figure 2b). Because DTT had little, if any, effect on R271C and Q226C homomers (Figure 2b), it is likely that this increase in current size is mediated by heteromeric receptors, which can contain only one or two R271C–Q226C interfaces. Thus, the linking of only one or two intersubunit interfaces is sufficient to inhibit maximal current responses to glycine. This interpretation makes the assumption that the detected interaction is caused by an intersubunit 271–226 interaction and not an intersubunit 271–271 or 226–226 interaction in R271C–Q226C heteromers. We see two arguments against the latter possibility. First, in the $\alpha 1$ GlyR model, the distances between two adjacent R271 side chains and between two adjacent Q226 side chains are 20.5 and 18.8 Å, respectively (not shown), which are at the upper limit of distances that receptor positions traverse to form disulfide bonds.^{27,28} Second, given that the promotion of 271–271 or 226–226 interactions (by HgCl₂ at R271C and Q226C homomers) tends to increase current size (Figure 2b), it is unlikely that a DTT-induced increase in current is due to breaking of 271–271 or 226–226 interactions.

If our interpretations described above were correct, adjacent R271C/Q226C subunits would associate with greater stability than WT subunits, because of the introduced intersubunit disulfide link. To verify this, WT and mutant GlyRs were purified without DTT or β -mercaptoethanol and subjected to SDS–PAGE and Western blotting. This identified large amounts of \sim 45 kDa protein for each construct (Figure 2c), indicating the denaturation of pentameric receptors into single $\alpha 1$ GlyR subunits, which have a molecular mass of 48 kDa.²⁹




Figure 2. R271C/Q226C $\alpha 1$ GlyRs show altered function indicative of an intersubunit disulfide link. (a) Exemplary responses of R271C/Q226C cRNA-treated oocytes to 100 mM glycine alone (white bars) or in the presence of 2 mM DTT (gray bars). (b) Averaged responses (\pm SEM; $n = 3$ –9) to glycine (100 mM for mutants and 3 mM for WT) alone or in the presence of 2 mM DTT or 10 μ M HgCl₂, normalized to the response to glycine alone (I/I_{control}) after experiments illustrated in panel a. Compared to the response to glycine alone with ANOVA and Dunnett post hoc analysis, * $P < 0.05$ and *** $P < 0.001$. (c) Western blotting of purified $\alpha 1$ GlyRs. In the left panel, purified WT, R271C/Q226C (RC/QC), Q226C, and R271C $\alpha 1$ GlyRs separate into \sim 48 kDa bands indicative of single subunits but only R271C/Q226C (black arrow) and to a lesser extent R271C (white arrow) proteins retain an \sim 250 kDa oligomer, indicative of a pentameric form. In the right panel, the pentameric form of R271C/Q226C subunits (black star, RC/QC) is abolished by 10% β -mercaptoethanol (white star, RC/QC*); WT subunits run only as monomers in the absence (WT) and presence (WT*) of 10% β -mercaptoethanol. The black triangle denotes an \sim 100 kDa band for β -mercaptoethanol-treated R271C/Q226C subunits.

For R271C/Q226C subunits, however, a clear agglomeration of \sim 250 kDa was also identified (Figure 2c, black arrow; Figure 2 of the Supporting Information), indicating that an intersubunit link between the introduced cysteines stabilizes the pentameric form of R271C/Q226C receptors. A faint 250 kDa agglomeration was also observed for R271C subunits (Figure 2c, white arrow), indicating a pentameric form of R271C receptors. As R271C receptors contain only five TMD cysteines, the stabilization of the pentameric form cannot be a result of five intersubunit links in the TMD (which would require a total of 10 TMD cysteines). Rather, we interpret this

as the combined result of one to two intersubunit disulfide 271–271 links and various noncovalent intersubunit associations that can occur under mildly denaturing conditions. This interpretation is supported by the weak protein band at ~100 kDa for WT subunits (black arrow in Figure 2 of the Supporting Information), indicative of $\alpha 1$ GlyR subunit dimers.

To confirm that the association of R271C/Q226C subunits was due to a disulfide interaction, we compared association in the presence or absence of the reducing agent β -mercaptoethanol; 10% β -mercaptoethanol abolished the pentameric form of R271C/Q226C subunits (in Figure 2c, compare the black and white stars), leaving only monomeric (~45 kDa) and dimeric (~100 kDa) bands (Figure 2c, black triangle). This confirms that intersubunit noncovalent interactions stabilize $\alpha 1$ GlyR dimers and intersubunit disulfide links between introduced cysteines stabilize $\alpha 1$ GlyR pentamers. We acknowledge here an alternate interpretation of the pentameric R271C/Q226C protein band, that it is simply a more robust manifestation of intersubunit 271–271 interactions induced by the Q226C substitution. Because the electrophysiological data suggest that 271–271 interactions enhance currents whereas 271–226 interactions inhibit currents (as discussed above), we reason that the Q226C substitution would actually counteract 271–271 interactions, and we exclude this alternate interpretation. Thus, the biochemical experiments confirm that intersubunit disulfide links occur between subunits of R271C/Q226C $\alpha 1$ GlyRs and that the increased current size at R271C/Q226C $\alpha 1$ GlyRs in the presence of DTT is due to the release of these intersubunit M2–M1 links.

The Separation of M2 and M1 Positions in R271C/Q226C $\alpha 1$ GlyRs Increases during Activation. If two $\alpha 1$ GlyR positions are in the proximity of each other in a resting state, introduced cysteines may link spontaneously, such that reduction by DTT induces currents directly or enhances current responses to agonists.^{14,30} Conversely, introduced cysteines at some $\alpha 1$ GlyR positions link only upon repeated channel activation, suggesting that the relevant positions are brought together during the activation process.^{26,31} To establish if the intersubunit link in R271C/Q226C receptors is formed in a resting state or at a later stage of the activation process, we compared responses to repeated applications of glycine, before and after the application of DTT (Figure 3a), and we tested for enhancement of glycine responses by DTT when applied in the complete absence of glycine (Figure 3b). We found that the initial response to saturating glycine was not significantly different from the second or third responses, and a subsequent application of glycine in the presence of 2 mM DTT caused a significant increase in current (Figure 3a). Subsequent applications of glycine alone saw the current size decrease to its original level. Also, when DTT was applied to oocytes in the absence of glycine, subsequent responses to glycine were significantly enhanced (Figure 3b). This suggests that the intersubunit M2–M1 link is formed in a resting state. This is in contrast, for example, to an intrasubunit M2–M3 link in the $\alpha 1$ GlyR, which requires repeated applications of glycine to form.³¹ This also contrasts the intersubunit M2–M1 link shown in the $\alpha 1/\beta 2/\gamma 2$ GABA_AR, which forms after repeated agonist application.²² The GABA_AR M1 residue in that study equates to $\alpha 1$ GlyR I225, next to Q226 at the intersubunit interface but further from R271 and facing the surrounding membrane.²²

As $\alpha 1$ GlyRs are activated with increasing efficiency by one to five molecules of glycine (i.e., dependent on glycine concentration),³² we next questioned if breaking the M2–M1




Figure 3. Formation of the intersubunit link in R271C/Q226C receptors does not depend on repeated activation by glycine or on the concentration of glycine. (a) The left panel shows exemplary responses of R271C/Q226C $\alpha 1$ GlyR-expressing oocytes to repeated application of 100 mM glycine (white bars) before and after application in the presence of 2 mM DTT (gray bars). Oocytes were rinsed for ~10 min between subsequent glycine or DTT applications. The right panel shows responses were normalized to that in the presence of DTT and averaged (\pm SEM; $n = 6$). Compared to the initial response with ANOVA and Tukey post hoc analysis, $**P < 0.01$ and $***P < 0.001$. (b) The left panel shows responses to 100 mM glycine (white bars) at R271C/Q226C $\alpha 1$ GlyR-expressing oocytes are enhanced by 2 mM DTT (gray bars) in the absence of glycine and when co-applied with glycine. The right panel shows responses were normalized to the initial glycine response and averaged (\pm SEM; $n = 5$). Compared to the initial response with ANOVA and Tukey post hoc analysis, $*P < 0.05$ and $**P < 0.01$. (c) Glycine concentration–response data for WT and mutant $\alpha 1$ GlyR-expressing oocytes. Responses to each concentration of glycine were normalized to the maximal glycine-activated response (I/I_{\max}) and fit with nonlinear regression giving the parameters listed in Table 1. (d) Effects of DTT and HgCl₂ on glycine concentration–response data for R271C/Q226C $\alpha 1$ GlyR-expressing oocytes. Responses were normalized to the maximal response to glycine alone (I/I_{control}); for responses to glycine alone, data are from panel c and therefore are indicated only as a dotted line. Glycine EC₅₀ values were 3.4 ± 0.67 mM ($n = 7$), 3.8 ± 0.66 mM in the presence of DTT ($n = 6$), and 4.1 ± 0.56 mM in the presence of HgCl₂ ($n = 3$), which were not significantly different when compared via ANOVA.

link enhanced currents similarly at various glycine concentrations. If the enhancement were different at low and high concentrations, this could imply that the M2–M1 separation is differentially required by partially and fully liganded GlyR activation. We first established the glycine sensitivity of WT and mutant receptors in the absence of DTT and HgCl₂ (Figure 3c). Glycine EC₅₀ values for R271C, Q226C, and R271C/Q226C receptors were all significantly higher than for WT receptors (Table 1), indicating significantly decreased apparent

Table 1. Nonlinear Regression Parameters for Glycine Activation of $\alpha 1$ GlyRs^a and Double-Mutant Cycle Analysis Results^b

$\alpha 1$ GlyR	EC ₅₀ (mM)	n _H	I _{max} (μ A)	Ω^b
WT	0.04 \pm 0.01	2.0 \pm 0.1	6.5 \pm 0.7	
R271C	6.8 \pm 0.47 ^c	1.5 \pm 0.1	1.8 \pm 0.3 ^c	
Q226C	4.7 \pm 0.59 ^c	1.6 \pm 0.5	1.6 \pm 0.7 ^c	
R271C/Q226C	3.4 \pm 0.67 ^c	1.3 \pm 0.1	2.2 \pm 0.4 ^c	4.3 $\times 10^{-3}$

^aAll values are means \pm SEM from three to seven experiments. ^bThe coupling coefficient, Ω , was calculated with the equation $\Omega = (EC_{50,WT} \times EC_{50,R271C/Q226C}) / (EC_{50,R271C} \times EC_{50,Q226C})$. ^cSignificantly different from the WT value for that parameter ($P < 0.001$, ANOVA with Tukey post hoc analysis).

glycine affinity. R271C/Q226C receptors yielded a (non-significantly) lower EC₅₀ value than the single-mutant receptors, showing that the deleterious effects of the two single mutations on glycine sensitivity were not additive. We applied to these results double-mutant cycle analysis, which holds that mutations at two sites of no energetic or structural interaction will be multiplicative in their reduction of function, as indicated by an Ω value [(EC_{50,WT} \times EC_{50,double mutant}) / (EC_{50,mutant A} \times EC_{50,mutant B})] close to unity.³³ The Ω value for R271C/Q226C $\alpha 1$ GlyRs was 4.3 $\times 10^{-3}$ (Table 1), indicating that an energetic coupling of C271 and C226 affects the apparent glycine affinity. [In comparison, the combinations of C290S and R271C mutations or C290S and Q226C mutations yielded Ω values of 0.89 and 1.8, respectively (see Figure 1 of the Supporting Information).] If this energetic coupling was a direct effect of the disulfide link, the glycine EC₅₀ value of R271C/Q226C receptors should be increased (Ω brought closer to unity) by the presence of DTT. However, DTT enhanced responses to all concentrations of glycine similarly and thus had no significant effect on the glycine EC₅₀ value for R271C/Q226C receptors (Figure 3d). This would suggest that the energetic coupling of these positions, with regard to the apparent glycine affinity, does not lie in the disulfide interaction; however, a possible DTT-induced increase in EC₅₀ might be masked by desensitization during responses to high concentrations at unlinked receptors (compare traces 1 and 4 in Figure 3a). That DTT similarly enhanced responses to all concentrations of glycine suggests that the linking of M2 and M1 (at one or two intersubunit interfaces) prevents activation of both partially and fully liganded $\alpha 1$ GlyRs. Given that the EC₅₀ is determined by agonist affinity and gating efficacy, this also reveals the likely mechanism by which M2–M1 links decrease whole-cell currents: one to two M2–M1 links in individual receptors prevent ligand-induced activation, decreasing the number of receptors that contribute to the whole-cell current without affecting the agonist affinity or gating efficacy; reduction by DTT allows the separation of upper M2 from M1 and thus channel activation in individual receptors, increasing

the number of receptors that contribute to the whole-cell current. The fact that effects of R271C and Q226C mutations on the agonist EC₅₀ are coupled, as revealed by double-mutant cycle analysis, and this coupling is insensitive to DTT reiterates that upper M2 and upper M1 are both part of the conventional agonist-induced channel activation pathway,^{6,34} and that their linking in this study simply precludes any channel activation.

Activation of R271C/Q226C $\alpha 1$ GlyRs by Partial Agonists. β -Alanine and taurine are partial agonists at GlyRs, in that even at saturating concentrations, the maximal open probability they elicit at GlyR channels is less than that elicited by glycine.³⁵ β -Alanine and taurine bind to R271 mutant GlyRs but barely activate any detectable current,^{5,11} although the presence of propofol permits the activation of large currents by β -alanine.¹¹ We tested if DTT enhanced β -alanine- and taurine-activated currents at R271C/Q226C $\alpha 1$ GlyRs, to establish if the M2–M1 separation is similarly required by activation by full and partial agonists. Average current responses to 100 mM β -alanine and 100 mM taurine were 13 \pm 3 ($n = 4$) and 6 \pm 1 nA ($n = 5$), respectively, which were both substantially smaller than those activated by 100 mM glycine in the same series of experiments [0.4 \pm 0.1 μ A ($n = 5$); $P < 0.001$, ANOVA with Dunnett post hoc analysis]. In the presence of 2 mM DTT, average current responses to β -alanine and taurine were increased to 32 \pm 9 and 19 \pm 7 nA ($n = 7$) (Figure 4a), which are significantly greater than the initial




Figure 4. Currents activated by partial agonists are significantly enhanced by DTT. (a) Exemplary responses of R271C/Q226C $\alpha 1$ GlyR-expressing oocytes to 100 mM β -alanine alone (white bars) and 2 mM DTT (gray bars) or 500 μ M propofol (hashed bars). Propofol was used only to confirm robust activation by β -alanine.¹¹ (b) Currents in response to 100 mM β -alanine ($n = 4$) and 100 mM taurine ($n = 5$) alone (white columns) and in the presence of DTT (gray columns) were normalized to the response to partial agonists alone ($I/I_{control}$); error bars indicate the SEM. Compared to the control response with a paired t test, * $P < 0.05$ and ** $P < 0.01$.

responses (Figure 4b). Thus, the M2–M1 link has a similar inhibitory effect on both partial and full agonist activation, providing further evidence that transitions between different agonist-bound states are not affected by the link.

Enhancement by Propofol Is Not Affected by the M2–M1 Link. The intravenous general anesthetic propofol

depresses neuronal function by enhancing the activation of GlyRs and GABA_ARs.^{36–38} On the basis of homology with anesthetic-bound eukaryotic pLGICs and dynamic simulations of model GlyRs, it is predicted that propofol and functionally related drugs bind at the interface of adjacent subunits in the TMD, stabilizing the open channel.^{9,10} However, the binding site and the particular conformational changes influenced by propofol binding in the GlyR are unknown. In a final set of experiments, we therefore sought to establish if enhancement by propofol is affected by the linking of adjacent subunits in R271C/Q226C α 1 GlyRs. At M2–M1-linked receptors, i.e., R271C/Q226C receptors in the absence of DTT, 500 μ M propofol enhanced responses to a range of glycine concentrations, shifting the glycine EC₅₀ value from to 3.4 ± 0.67 to 1.3 ± 0.50 mM (Figure 5a,b). At M2–M1-unlinked receptors, R271C/Q226C receptors in the presence of DTT, 500 μ M propofol caused essentially identical enhancement of responses to glycine (compare filled and empty symbols in Figure 5b), shifting the glycine EC₅₀ value from 3.8 ± 0.66 to 1.5 ± 0.48 mM. This suggests that the intersubunit link has no effect on the ability of propofol to enhance channel activation. We reach a similar conclusion when we compare the individual increases in current caused by DTT and propofol to the total increase in current caused by the combined presence of both DTT and propofol. Currents activated by 1 mM Gly (approximately an EC₂₀ concentration) were enhanced 4.0 ± 1.3 -fold by 2 mM DTT and 8.1 ± 1.4 -fold by 500 μ M propofol (Figure 5c). The combined presence of 2 mM DTT and 500 μ M propofol caused a 20.8 ± 2.6 -fold increase, significantly greater than the increase caused by either treatment alone (Figure 5c). The same combined effect was observed with saturating glycine concentrations (Figure 5c), implying that mechanisms of DTT- and propofol-mediated enhancement remain distinct at all glycine concentrations. Considering that (1) DTT unlinks individual receptors, thereby increasing the number of channels contributing to the whole-cell current, (2) propofol affects the apparent glycine affinity and agonist efficacy,¹¹ and (3) the whole-cell current is proportional to both the number of functional receptors and the open probability of individual receptors, it is logical that the effects of DTT and propofol are additive (Figure 5c).

Binding sites for propofol in GlyRs have not been identified, although several molecular determinants of propofol sensitivity have been identified in the receptor TMD. A serine–isoleucine mutation at the M2-S267 position of α 1 GlyRs does not affect enhancement by propofol but abolishes the direct activation by high concentrations of propofol.⁵⁸ In α 1 β 2 γ 2 GABA_ARs, an asparagine–methionine mutation at the equivalent position in the β 2 subunit decreases the sensitivity to enhancement by propofol,³⁹ and in α 2 β 1 γ 2 GABA_ARs, a methionine–tryptophan substitution at the β 1 position equivalent to α 1 GlyR M3-288 decreases the sensitivity to enhancement by propofol.⁴⁰ The side chains of both of these positions are likely oriented into the intersubunit cavity, according to GlyR and GABA_AR models based on both prokaryotic pLGICs and the *C. elegans* α GluCl.^{18,22,41} Taken together, it seems that the enhancing actions of propofol at GlyRs and GABA_ARs depend on side chains in the intersubunit cavity but not on the ability of the R271 position to separate from the Q226 position during activation by glycine.

Functional Rearrangement of the M2-R271 Position during pLGIC Activation. As a mechanistic explanation for these results, we envisage that the separation of the M2-271




Figure 5. Enhancement of α 1 GlyR currents by propofol is not affected by the intersubunit link. (a) Exemplary responses of oocytes treated with R271C/Q226C α 1 GlyR cRNA to 1 mM glycine alone (white bars) or in the presence of 500 μ M propofol (hashed bars), 2 mM DTT (gray bars), or 500 μ M propofol and 2 mM DTT. (b) Responses to glycine alone (\square) or in the presence of propofol (\circ) were normalized to the maximal response to glycine alone, and responses to glycine in the presence DTT (\blacksquare) and in the combined presence of DTT and propofol (\bullet) were normalized to the maximal response to glycine in the presence of DTT. Average glycine EC₅₀ values [mean \pm SEM ($n = 4-7$)] under these conditions were 3.4 ± 0.67 (\square), 1.3 ± 0.50 (\circ), 3.8 ± 0.66 (\blacksquare), and 1.5 ± 0.48 mM (\bullet). (Data for glycine alone or in the presence of DTT are essentially repeated from Figure 3, and fits are therefore shown as dashed lines.) (c) Responses to 1 and 100 mM glycine alone (white columns) and in the presence of 2 mM DTT, 500 μ M propofol, or both, normalized to the response to glycine alone (I/I_{Gly}). For both glycine concentrations, the responses in the presence of DTT or propofol were compared to the response in the combined presence of DTT and propofol by ANOVA and Dunnett post hoc analysis (** $P < 0.01$; *** $P > 0.001$).

and M1-226 positions is minimal at rest and then increases either during an early stage of the activation process, such as ligand-induced “flipping” or “priming” of channel opening,^{42,43} or during channel opening. This is based on the following

reasons. First, we observed no spontaneous activation of R271C/Q226C receptors in the absence of agonist (in the absence or presence of HgCl₂), suggesting that the proximity of the two positions does not correspond to an open-channel state. Second, we showed that activation does not bring the positions closer together; they are already in the proximity of each other at rest, and enforced or prolonged proximity prevents channel activation. Finally, the M2 position in nAChRs equivalent to R271 in $\alpha 1$ GlyRs is suggested to rearrange shortly after ligand binding but before M2 residues in the channel pore rearrange to open the channel,⁴⁴ suggesting by homology that rearrangement of this position in the $\alpha 1$ GlyR couples conformational changes in the LBD to conformational changes in the channel domain by rearranging before the channel gate opens.⁴⁴ It is interesting that the linking of one or two M2–M1 interfaces (in R271C–Q226C heteromers) prevented activation to an extent similar to the extent of potential linking of five interfaces (in R271C/Q226C homomers). This implies that the contributions of five intersubunit interfaces to channel activation do not sum linearly. This reflects the nonsymmetrical contribution of agonist binding subunits to agonist-induced channel activation and contrasts with the symmetrical contribution of deeper, pore-lining M2 residues to channel conductance in nAChRs and nAChR–5-HT₃R chimeras,^{45,46} further indicative of a role for position 271 of $\alpha 1$ GlyR in coupling agonist binding with channel activation.

If R271 is moved away from Q226 during activation, to where is it moved? Our site-directed cross-linking approach failed to establish if position 271 interacts with position 284 in M3, as mutant D284C subunits were expressed but did not respond to ligands. This nonetheless identifies M3-D284 as a crucial component of the ligand activation pathway. Notably, in a prokaryotic pLGIC activated by pH, the disulfide linking of positions equivalent to positions 271 and 284 of $\alpha 1$ GlyR activated currents in the absence of agonist.¹⁴ This suggests that in this homologue, activation involves an increased level of association of M2 and M3 helices, which could be the very mechanism by which protons activate this pLGIC.⁴⁷ Although caution must be exercised in likening amino acid rearrangement in the GlyR to that in other pLGICs,⁴⁸ a rigid-body, outward tilting of the upper half of M2 helices seems to be a common feature of GABA_ARs, nAChRs, 5-HT₃Rs, and prokaryotic pLGICs.^{15,17,49–53} We acknowledge that across different receptors, this outward tilting could involve different relations to other helices, illustrated by the fact that the R271–Q226 *Ca* separation ($\alpha 1$ GlyR numbering) does not correlate with channel state in currently available pLGIC crystal structures (9.9 Å in closed-channel ELIC, 7.5 Å in open-channel GLIC, and 9.0 Å in open-channel GluCl).^{15–17} These results nonetheless confirm that the open-channel GluCl provides a suitable template for establishing the proximity of $\alpha 1$ GlyR amino acid residues and, in combination with site-directed cross-linking, if proximity corresponds to closed- or open-channel states.

In the $\alpha 1$ GlyR, outward movement of the upper portion of M2 during channel activation would mean that the set of M3 (in the same subunit) and M1 (in the adjacent subunit) side chains that neighbor M2-271 would differ in resting/closed versus activated/open (or intermediary) channel states. This is reflected in the findings that the signal of a fluorophore attached to position 271 shifts during glycine activation of $\alpha 1$ GlyRs to indicate a more hydrophobic environment,⁷ glycine

activation of $\alpha 1$ GlyRs increases the strength of association of introduced cysteines at M2-267 (one helical turn internal to R271) and M3-288 (one helical turn internal to D284),³¹ and the arginine side chain at position 271 is no longer important to glycine potency if the surrounding microenvironment is significantly altered by numerous amino acid substitutions.¹² The transition of the R271 side chain to a more hydrophobic environment is intriguing when compared to results at $\alpha 1/\beta 2/\gamma 2$ GABA_ARs, where activation by GABA induces linking of the M2-271 position to the M1-225 position (both $\alpha 1$ GlyR numbering). The M1-225 position is farther from the pore than Q226, is closer to M3 and the surrounding membrane, and is occupied by an isoleucine residue in the $\alpha 1$ GlyR.²² We speculate that during agonist-induced activation, the R271 side chain is moved from a hydrophilic environment close to the Q226 side chain to a more hydrophobic environment deeper in the intersubunit cavity and closer to M3. A rotation of the M2 helix along its long axis, as is suggested for nAChRs and GABA_ARs,^{25,54} would foreseeably facilitate this rearrangement. Conservation of this rearrangement across GlyRs and GABA_ARs could explain the similar decreases in agonist potency caused by the mutation of $\alpha 1$ R271 in heteromeric $\alpha 1/\beta$ GlyRs and of $\beta 2$ R269 in heteromeric $\alpha 1/\beta 2/\gamma 2$ GABA_ARs.^{4,22}

Concluding Remarks. These results show that in cysteine-substituted $\alpha 1$ GlyRs, side chains at positions M2-271 and M1-226 of adjacent subunits are in the proximity of each other at rest and that their covalent linking at one to two intersubunit interfaces prevents channel activation by agonists. Mutant proteins differ from WT proteins in the range of conformations they are likely to adopt,⁵⁵ but we liken the rearrangement of the mutated M2-271 position to that in WT $\alpha 1$ GlyRs and indeed to those in other pLGICs, based on evidence that at various pLGICs, the upper half of M2 moves away from the pore axis,¹⁷ M2 interactions with M3 (which is farther from the pore than M2) are enhanced,^{31,53} and the relation of M2 to M1 of the adjacent subunit is altered^{16,22} in the activation process. Our results show that, in contrast to activation by agonists, enhancement by propofol does not rely on the separation of adjacent M2 and M1 helices in the TMD. Therefore, the enhancing effect of propofol is likely via an allosteric pathway different from that activated by glycine,¹² and despite possibly binding in this vicinity,¹⁰ propofol must target some other rearrangement related to channel activation and/or conductance.

METHODS

Chemicals. Glycine, NaCl, KCl, CaCl₂, MgCl₂, HEPES, Tris, Na₂HPO₄, dodecyl maltoside, protease inhibitor, dimethyl sulfoxide, Rotiphorese gel mix, and skim milk powder were purchased from Carl Roth GmbH (Karlsruhe, Germany). NaOH was from AppliChem GmbH (Darmstadt, Germany). Nickel-NTA agarose beads were from Qiagen (Munich, Germany). Propofol (2,6-diisopropylphenol), dithiothreitol (DTT), HgCl₂, tricine, gentamicin, type IIA collagenase, imidazole, Triton X-100, and deoxycholate were from Sigma-Aldrich (Munich, Germany). Polyvinylidene fluoride (PDVF) membranes were from Bio-Rad (Hilden, Germany). Stocks of glycine (1 M), DTT (400 mM), and HgCl₂ (10 mM) were prepared in a bath solution (components in Electrophysiological Experiments), and 1 M stocks of propofol were prepared in dimethyl sulfoxide. Stocks were stored at –20 °C, and experimental solutions were prepared from stocks on the day of the experiments.

Site-Directed Mutagenesis and cRNA Synthesis. The template cDNA for site-directed mutagenesis was a C-terminally His-tagged

human GlyR $\alpha 1$ subunit in the pNKS2 vector.²¹ Mutant cDNAs were generated with the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies, Böblingen, Germany), and for all generated clones, the appropriate sequence of the entire $\alpha 1$ GlyR insert was confirmed (Eurofins MWG Operon, Ebersberg, Germany). cDNAs were linearized with NotI (New England Biolabs GmbH, Frankfurt, Germany), and cRNAs were synthesized with the mMACHINE SP6 Kit (Life Technologies GmbH, Darmstadt, Germany).

As approved by the Technical University of Darmstadt (Agreement V54-19c20/15 DA8/Anz. 20), oocytes were removed from female *Xenopus laevis* frogs anesthetized with 0.3% Tricaine and transferred to frog Ringer's solution [96 mM NaCl, 2 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, and 5 mM HEPES (pH 7.4 with NaOH)] supplemented with 50 mg/mL gentamycin. Oocytes were prepared as described by Laube et al.⁵⁶ Briefly, stage V or VI oocytes were isolated manually, defolliculated by a 2 h incubation in type IIA collagenase, rinsed with Ca²⁺-free frog Ringer's solution, and stored in frog Ringer's solution at 18 °C. Oocytes were treated with 4 ng of cRNA (at 100 ng/ μ L); in experiments in which oocytes were treated with two different constructs, 2 ng of each was injected. Treated oocytes were then incubated in frog Ringer's solution at 18 °C until the experiments were conducted.

Electrophysiological Experiments. Two to five days after injection, oocytes were transferred to a recording chamber where they were continuously perfused with a bath solution [115 mM NaCl, 1 mM KCl, 1.8 mM CaCl₂, and 10 mM Hepes (pH 7.4 with NaOH)] or drugs dissolved in a bath solution. For two-electrode voltage-clamp recordings, microelectrodes were filled with 3 M KCl, oocytes were clamped at -70 mV, and currents were recorded at 200 Hz with a Geneclamp 500B amplifier, a Digidata 1322A interface, and Clampex version 9.2 (Molecular Devices, Sunnyvale, CA). In glycine dose-response experiments, peak current responses to glycine at increasing concentrations were measured, and these were plotted against concentration and fit with variable slope nonlinear regression (Prism 4, GraphPad Software Inc., San Diego, CA), generating EC₅₀ and n_H values. These were averaged for each construct and reported as means \pm SEM. In a test of the effects of DTT and HgCl₂, the oocyte was perfused in either 2 mM DTT or 10 μ M HgCl₂ for 100 s before application of glycine in the presence of 2 mM DTT or HgCl₂. The effects of propofol were tested by perfusing the oocyte with 500 μ M propofol for 30 s before applying glycine in the presence of 500 μ M propofol. Increases or decreases in the peak current response to glycine caused by DTT, HgCl₂, or propofol were generally expressed as the fraction of the response to glycine alone. This fraction was calculated for each oocyte, and the mean \pm SEM was calculated for each construct. In all experiments, each construct was tested in at least two batches of oocytes, alongside at least two other constructs.

Statistical Analysis. For glycine dose-response experiments, EC₅₀, n_H , and I_{max} values (mean \pm SEM) were compared by ANOVA and a Tukey post hoc analysis (Prism 4). In a test of the modulation of current responses by DTT and HgCl₂, each construct was statistically analyzed separately: the averaged fractional responses (mean \pm SEM) after the application of DTT or HgCl₂ were compared by ANOVA and a Dunnett post hoc analysis to control responses for the respective construct (Prism 4). Statistical significance was interpreted as P values of <0.05 or as otherwise indicated in the text and tables.

Western Blotting and Surface Labeling. After expression for 2–3 days, 10 oocytes per construct were rinsed three times with frog Ringer's solution and incubated for 10 min in frog Ringer's solution containing glycine at an EC₅₀ concentration. For surface labeling, oocytes were then incubated at 4 °C in frog Ringer's solution containing Cy5 NHS ester (GE Healthcare, Freiburg, Germany) for 1 h. Oocytes were then lysed by repeated pipetting in 100 μ L of a lysis solution [50 mM Tris, 150 mM NaCl, 0.5% Triton X-100, and 0.5% deoxycholate (pH 7.5)] and 20 brief steps of sonication on ice. The resulting homogenate was spun for 10 min at 15000g and 4 °C to isolate protein. His-tagged protein was bound to Ni²⁺ beads by rinsing protein for 30 min at 4 °C in wash buffer [100 mM Na₂HPO₄, 0.5% dodecyl maltoside, 0.1% protease inhibitor, and 30 mM imidazole (pH

8.0)] containing 10% Ni²⁺ beads. Protein was rinsed in wash buffer (containing 30 mM imidazole) and eluted in a solution containing 20 mM Tris, 0.5% dodecyl maltoside, 200 mM imidazole, and 10 mM EDTA (pH 8.0), as described by Haeger et al.²¹ Protein was then isolated by spinning for 2 min at 15000g and 4 °C and stored at -80 °C. For Western blotting, a third of the total protein from 10 oocytes was added to 40 mM Tris-HCl, 2% SDS, bromophenol blue, and, where appropriate, 10% β -mercaptoethanol, if indicated treated for 1 h at 37 °C in Endo H (New England Biolabs GmbH), heated for 5 min at 95 °C, and added to an 8% Rotiphere gel for separation. If prestained with Cy5, the gel was imaged via ChemiDoc MP (Bio-Rad). For Western blots, the gel was transferred to PDVF membranes for blotting. Membranes were first blocked with 5% skim milk, subsequently incubated in mAb2b, a primary antibody that is specific for $\alpha 1$ GlyRs,⁵⁷ and finally incubated in horseradish peroxidase-conjugated goat anti-mouse IgG (Bio-Rad). Membranes were developed via ChemiDoc MP.

■ ASSOCIATED CONTENT

📄 Supporting Information

Two figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Schnittspahnstrasse 3, 64287 Darmstadt, Germany. E-mail: lynagh@bio.tu-darmstadt.de.

Author Contributions

T.L. and A.K. designed and performed the experiments. T.L., A.K., and B.L. analyzed the data. T.L. and B.L. prepared the manuscript.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Brett Giolma for help with electrophysiological experiments and Adriana Längle and Dr. Wibke Wagner for help with biochemical experiments.

■ ABBREVIATIONS

ANOVA, analysis of variance; 5-HT₃Rs, 5-HT type 3 receptors; DTT, dithiothreitol; ECD, extracellular domain; GABA, γ -aminobutyric acid; GABA_AR, γ -aminobutyric acid type A receptor; Gly, glycine; GlyR, inhibitory glycine receptor; LBD, ligand-binding domain; M2, membrane-spanning helix 2; M3, membrane-spanning helix 3; nAChR, nicotinic acetylcholine receptor; pLGIC, pentameric ligand-gated ion channel; Prop, propofol (2,6-diisopropylphenol); SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SEM, standard error of the mean; TMD, transmembrane domain

■ REFERENCES

- (1) Changeux, J. P. (2010) Allosteric receptors: From electric organ to cognition. *Annu. Rev. Pharmacol. Toxicol.* 50, 1–38.
- (2) Betz, H., and Laube, B. (2006) Glycine receptors: Recent insights into their structural organization and functional diversity. *J. Neurochem.* 97, 1600–1610.
- (3) Purohit, P., Mitra, A., and Auerbach, A. (2007) A stepwise mechanism for acetylcholine receptor channel gating. *Nature* 446, 930–933.
- (4) Langosch, D., Laube, B., Rundstrom, N., Schmieden, V., Bormann, J., and Betz, H. (1994) Decreased agonist affinity and chloride conductance of mutant glycine receptors associated with human hereditary hyperekplexia. *EMBO J.* 13, 4223–4228.

- (5) Rajendra, S., Lynch, J. W., Pierce, K. D., French, C. R., Barry, P. H., and Schofield, P. R. (1995) Mutation of an arginine residue in the human glycine receptor transforms β -alanine and taurine from agonists into competitive antagonists. *Neuron* 14, 169–175.
- (6) Lynch, J. W., Rajendra, S., Pierce, K. D., Handford, C. A., Barry, P. H., and Schofield, P. R. (1997) Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. *EMBO J.* 16, 110–120.
- (7) Pless, S. A., Dibas, M. I., Lester, H. A., and Lynch, J. W. (2007) Conformational variability of the glycine receptor M2 domain in response to activation by different agonists. *J. Biol. Chem.* 282, 36057–36067.
- (8) Shiang, R., Ryan, S. G., Zhu, Y. Z., Hahn, A. F., O'Connell, P., and Wasmuth, J. J. (1993) Mutations in the $\alpha 1$ subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperkplexia. *Nat. Genet.* 5, 351–358.
- (9) Murail, S., Wallner, B., Trudell, J. R., Bertaccini, E., and Lindahl, E. (2011) Microsecond simulations indicate that ethanol binds between subunits and could stabilize an open-state model of a glycine receptor. *Biophys. J.* 100, 1642–1650.
- (10) Sauguet, L., Howard, R. J., Malherbe, L., Lee, U. S., Corringer, P. J., Adron Harris, R., and Delarue, M. (2013) Structural basis for potentiation by alcohols and anaesthetics in a ligand-gated ion channel. *Nat. Commun.* 4, 1697.
- (11) O'Shea, S. M., Becker, L., Weiher, H., Betz, H., and Laube, B. (2004) Propofol restores the function of "hyperkplexic" mutant glycine receptors in *Xenopus* oocytes and mice. *J. Neurosci.* 24, 2322–2327.
- (12) Shan, Q., Han, L., and Lynch, J. W. (2012) Function of hyperkplexia-causing $\alpha 1R271Q/L$ glycine receptors is restored by shifting the affected residue out of the allosteric signalling pathway. *Br. J. Pharmacol.* 165, 2113–2123.
- (13) Falke, J. J., and Koshland, D. E., Jr. (1987) Global flexibility in a sensory receptor: A site-directed cross-linking approach. *Science* 237, 1596–1600.
- (14) Prevost, M. S., Sauguet, L., Nury, H., Van Renterghem, C., Huon, C., Poitevin, F., Baaden, M., Delarue, M., and Corringer, P. J. (2012) A locally closed conformation of a bacterial pentameric proton-gated ion channel. *Nat. Struct. Mol. Biol.* 19, 642–649.
- (15) Bocquet, N., Nury, H., Baaden, M., Le Poupon, C., Changeux, J. P., Delarue, M., and Corringer, P. J. (2009) X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. *Nature* 457, 111–114.
- (16) Hibbs, R. E., and Gouaux, E. (2011) Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* 474, 54–60.
- (17) Hilf, R. J., and Dutzler, R. (2008) X-ray structure of a prokaryotic pentameric ligand-gated ion channel. *Nature* 452, 375–379.
- (18) Lynagh, T., Webb, T. I., Dixon, C. L., Cromer, B. A., and Lynch, J. W. (2011) Molecular determinants of ivermectin sensitivity at the glycine receptor chloride channel. *J. Biol. Chem.* 286, 43913–43924.
- (19) Arnon, R., and Shapira, E. (1969) Crystalline papain derivative containing an intramolecular mercury bridge. *J. Biol. Chem.* 244, 1033–1038.
- (20) Cleland, W. W. (1964) Dithiothreitol, a New Protective Reagent for SH Groups. *Biochemistry* 3, 480–482.
- (21) Haeger, S., Kuzmin, D., Detro-Dassen, S., Lang, N., Kilb, M., Tsetlin, V., Betz, H., Laube, B., and Schmalzing, G. (2010) An intramembrane aromatic network determines pentameric assembly of Cys-loop receptors. *Nat. Struct. Mol. Biol.* 17, 90–98.
- (22) Bali, M., and Akabas, M. H. (2012) Gating-induced conformational rearrangement of the γ -aminobutyric acid type A receptor β - α subunit interface in the membrane-spanning domain. *J. Biol. Chem.* 287, 27762–27770.
- (23) Jansen, M., and Akabas, M. H. (2006) State-dependent cross-linking of the M2 and M3 segments: Functional basis for the alignment of GABA_A and acetylcholine receptor M3 segments. *J. Neurosci.* 26, 4492–4499.
- (24) Sowdhamini, R., Srinivasan, N., Shoichet, B., Santi, D. V., Ramakrishnan, C., and Balaram, P. (1989) Stereochemical modeling of disulfide bridges. Criteria for introduction into proteins by site-directed mutagenesis. *Protein Eng., Des. Sel.* 3, 95–103.
- (25) Horenstein, J., Wagner, D. A., Czajkowski, C., and Akabas, M. H. (2001) Protein mobility and GABA-induced conformational changes in GABA(A) receptor pore-lining M2 segment. *Nat. Neurosci.* 4, 477–485.
- (26) McCracken, L. M., McCracken, M. L., Gong, D. H., Trudell, J. R., and Harris, R. A. (2010) Linking of Glycine Receptor Transmembrane Segments Three and Four Allows Assignment of Intrasubunit-Facing Residues. *ACS Chem. Neurosci.* 1, 482.
- (27) Careaga, C. L., and Falke, J. J. (1992) Thermal motions of surface α -helices in the D-galactose chemosensory receptor. Detection by disulfide trapping. *J. Mol. Biol.* 226, 1219–1235.
- (28) Horenstein, J., Riegelhaupt, P., and Akabas, M. H. (2005) Differential protein mobility of the γ -aminobutyric acid, type A, receptor α and β subunit channel-lining segments. *J. Biol. Chem.* 280, 1573–1581.
- (29) Grenningloh, G., Rienitz, A., Schmitt, B., Methfessel, C., Zensen, M., Beyreuther, K., Gundelfinger, E. D., and Betz, H. (1987) The strychnine-binding subunit of the glycine receptor shows homology with nicotinic acetylcholine receptors. *Nature* 328, 215–220.
- (30) Todorovic, J., Welsh, B. T., Bertaccini, E. J., Trudell, J. R., and Mihic, S. J. (2010) Disruption of an intersubunit electrostatic bond is a critical step in glycine receptor activation. *Proc. Natl. Acad. Sci. U.S.A.* 107, 7987–7992.
- (31) Lobo, I. A., Trudell, J. R., and Harris, R. A. (2004) Cross-linking of glycine receptor transmembrane segments two and three alters coupling of ligand binding with channel opening. *J. Neurochem.* 90, 962–969.
- (32) Beato, M., Groot-Kormelink, P. J., Colquhoun, D., and Sivilotti, L. G. (2002) Openings of the rat recombinant $\alpha 1$ homomeric glycine receptor as a function of the number of agonist molecules bound. *J. Gen. Physiol.* 119, 443–466.
- (33) Gleitsman, K. R., Shanata, J. A., Frazier, S. J., Lester, H. A., and Dougherty, D. A. (2009) Long-range coupling in an allosteric receptor revealed by mutant cycle analysis. *Biophys. J.* 96, 3168–3178.
- (34) Pless, S. A., Leung, A. W., Galpin, J. D., and Ahern, C. A. (2011) Contributions of conserved residues at the gating interface of glycine receptors. *J. Biol. Chem.* 286, 35129–35136.
- (35) Lape, R., Colquhoun, D., and Sivilotti, L. G. (2008) On the nature of partial agonism in the nicotinic receptor superfamily. *Nature* 454, 722–727.
- (36) Franks, N. P., and Lieb, W. R. (1994) Molecular and cellular mechanisms of general anaesthesia. *Nature* 367, 607–614.
- (37) Hales, T. G., and Lambert, J. J. (1991) The actions of propofol on inhibitory amino acid receptors of bovine adrenomedullary chromaffin cells and rodent central neurones. *Br. J. Pharmacol.* 104, 619–628.
- (38) Nguyen, H. T., Li, K. Y., daGraca, R. L., Delphin, E., Xiong, M., and Ye, J. H. (2009) Behavior and cellular evidence for propofol-induced hypnosis involving brain glycine receptors. *Anesthesiology* 110, 326–332.
- (39) Siegwart, R., Krahenbuhl, K., Lambert, S., and Rudolph, U. (2003) Mutational analysis of molecular requirements for the actions of general anaesthetics at the γ -aminobutyric acidA receptor subtype, $\alpha 1\beta 2\gamma 2$. *BMC Pharmacol.* 3, 13.
- (40) Krasowski, M. D., Koltchine, V. V., Rick, C. E., Ye, Q., Finn, S. E., and Harrison, N. L. (1998) Propofol and other intravenous anaesthetics have sites of action on the γ -aminobutyric acid type A receptor distinct from that for isoflurane. *Mol. Pharmacol.* 53, 530–538.
- (41) Bertaccini, E. J., Wallner, B., Trudell, J. R., and Lindahl, E. (2010) Modeling anesthetic binding sites within the glycine $\alpha 1$ receptor based on prokaryotic ion channel templates: The problem with TM4. *J. Chem. Inf. Model.* 50, 2248–2255.
- (42) Burzomato, V., Beato, M., Groot-Kormelink, P. J., Colquhoun, D., and Sivilotti, L. G. (2004) Single-channel behavior of heteromeric

$\alpha 1\beta$ glycine receptors: An attempt to detect a conformational change before the channel opens. *J. Neurosci.* 24, 10924–10940.

(43) Mukhtasimova, N., Lee, W. Y., Wang, H. L., and Sine, S. M. (2009) Detection and trapping of intermediate states priming nicotinic receptor channel opening. *Nature* 459, 451–454.

(44) Bafna, P. A., Purohit, P. G., and Auerbach, A. (2008) Gating at the mouth of the acetylcholine receptor channel: Energetic consequences of mutations in the $\alpha M2$ -cap. *PLoS One* 3, e2515.

(45) Labarca, C., Nowak, M. W., Zhang, H., Tang, L., Deshpande, P., and Lester, H. A. (1995) Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. *Nature* 376, 514–516.

(46) Rayes, D., De Rosa, M. J., Sine, S. M., and Bouzat, C. (2009) Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors. *J. Neurosci.* 29, 6022–6032.

(47) Wang, H. L., Cheng, X., and Sine, S. M. (2012) Intramembrane proton binding site linked to activation of bacterial pentameric ion channel. *J. Biol. Chem.* 287, 6482–6489.

(48) Dougherty, D. A. (2008) Cys-loop neuroreceptors: Structure to the rescue? *Chem. Rev.* 108, 1642–1653.

(49) Akabas, M. H., Kaufmann, C., Archdeacon, P., and Karlin, A. (1994) Identification of acetylcholine receptor channel-lining residues in the entire M2 segment of the α subunit. *Neuron* 13, 919–927.

(50) Cymes, G. D., Ni, Y., and Grosman, C. (2005) Probing ion-channel pores one proton at a time. *Nature* 438, 975–980.

(51) Paas, Y., Gibor, G., Grailhe, R., Savatier-Duclert, N., Dufresne, V., Sunesen, M., de Carvalho, L. P., Changeux, J. P., and Attali, B. (2005) Pore conformations and gating mechanism of a Cys-loop receptor. *Proc. Natl. Acad. Sci. U.S.A.* 102, 15877–15882.

(52) Velisetty, P., Chalamalasetti, S. V., and Chakrapani, S. (2012) Conformational transitions underlying pore opening and desensitization in membrane-embedded *Gloeobacter violaceus* ligand-gated ion channel (GLIC). *J. Biol. Chem.* 287, 36864–36872.

(53) Xu, M., and Akabas, M. H. (1993) Amino acids lining the channel of the γ -aminobutyric acid type A receptor identified by cysteine substitution. *J. Biol. Chem.* 268, 21505–21508.

(54) Unwin, N. (1995) Acetylcholine receptor channel imaged in the open state. *Nature* 373, 37–43.

(55) Kar, G., Keskin, O., Gursoy, A., and Nussinov, R. (2010) Allosterity and population shift in drug discovery. *Curr. Opin. Pharmacol.* 10, 715–722.

(56) Laube, B., Kuhse, J., and Betz, H. (2000) Kinetic and mutational analysis of Zn^{2+} modulation of recombinant human inhibitory glycine receptors. *J. Physiol. (Oxford, U.K.)* 522 (Part 2), 215–230.

(57) Hirzel, K., Muller, U., Latal, A. T., Hulsmann, S., Grudzinska, J., Seeliger, M. W., Betz, H., and Laube, B. (2006) Hyperekplexia phenotype of glycine receptor $\alpha 1$ subunit mutant mice identifies Zn^{2+} as an essential endogenous modulator of glycinergic neurotransmission. *Neuron* 52, 679–690.

(58) Ahrens, J., Leuwer, M., Stachura, S., Krampfl, K., Belelli, D., Lamber, J. J., and Haeseler, G. (2008) A transmembrane residue influences the interaction of propofol with the strychnine-sensitive glycine receptor $\alpha 1$ and $\alpha 1\beta$ receptor. *Anesth. Analg.* 107, 1875–1883.